Mesa Laboratories, Inc. (MLAB) Insider Trading Activity

NASDAQ$104.84+1.78 (1.73%)
Market Cap
$569.39M
Sector
Technology
Industry
Hardware, Equipment & Parts
Rank in Sector
97 of 583
Rank in Industry
7 of 71

MLAB Insider Trading Activity

MLAB Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$452,076
3
50
Sells
$296,501
3
50

Related Transactions

Ladiwala Shiraz Shabanalidirector
1
$252,805
0
$0
$252,805
Tripeny R Tonydirector
1
$99,940
0
$0
$99,940
Capone Mark Christopherdirector
1
$99,331
0
$0
$99,331
Archbold Brian DavidSVP Operations
0
$0
1
$45,840
$-45,840
Sakys JohnCFO
0
$0
1
$62,350
$-62,350
Owens Gary MPresident and CEO
0
$0
1
$188,312
$-188,312

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Insider Activity of Mesa Laboratories, Inc.

Over the last 12 months, insiders at Mesa Laboratories, Inc. have bought $452,076 and sold $296,501 worth of Mesa Laboratories, Inc. stock.

On average, over the past 5 years, insiders at Mesa Laboratories, Inc. have bought $276,038 and sold $5.94M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Ladiwala Shiraz Shabanali (director) — $252,805. Tripeny R Tony (director) — $99,940. Capone Mark Christopher (director) — $99,331.

The last purchase of 1,301 shares for transaction amount of $99,331 was made by Capone Mark Christopher (director) on 2026‑03‑10.

List of Insider Buy and Sell Transactions, Mesa Laboratories, Inc.

2026-03-10PurchaseLadiwala Shiraz Shabanalidirector
3,500
0.0522%
$72.23
$252,805
+14.20%
2026-03-10PurchaseTripeny R Tonydirector
1,315
0.0206%
$76.00
$99,940
+14.20%
2026-03-10PurchaseCapone Mark Christopherdirector
1,301
0.0205%
$76.35
$99,331
+14.20%
2025-06-16SaleOwens Gary MPresident and CEO
1,939
0.0359%
$97.12
$188,312
-17.76%
2025-06-16SaleSakys JohnCFO
642
0.0119%
$97.12
$62,350
-17.76%
2025-06-16SaleArchbold Brian DavidSVP Operations
472
0.0087%
$97.12
$45,840
-17.76%
2025-03-19SaleOwens Gary MPresident and CEO
21,000
0.3855%
$123.91
$2.6M
-34.41%
2024-10-29SaleOwens Gary MPresident and CEO
2,551
0.0469%
$111.98
$285,651
-0.36%
2024-10-28SaleOwens Gary MPresident and CEO
2,518
0.0395%
$113.62
$286,085
-0.48%
2024-09-13SaleArchbold Brian DavidSVP Operations
1,499
0.0276%
$125.00
$187,375
-5.47%
2023-12-15SaleArchbold Brian DavidSVP Operations
1,500
0.0282%
$112.36
$168,540
-1.59%
2023-09-15SaleSchmieder John Bradleydirector
1,000
0.0187%
$123.74
$123,740
-15.56%
2023-09-14SaleSchmieder John Bradleydirector
3,000
0.0546%
$123.05
$369,150
-17.19%
2023-09-13SaleSchmieder John Bradleydirector
3,000
0.0559%
$123.32
$369,965
-15.24%
2023-09-01SaleOwens Gary MPresident and CEO
2,000
0.0378%
$142.82
$285,640
-26.09%
2023-03-24SaleSakys JohnCFO
1,128
0.0207%
$167.01
$188,387
-33.28%
2023-03-22SaleSakys JohnCFO
2,500
0.0475%
$171.62
$429,050
-31.97%
2023-03-15SaleSakys JohnCFO
1,000
0.0185%
$165.71
$165,710
-27.37%
2023-03-09SaleSakys JohnCFO
400
0.0074%
$169.97
$67,988
-28.54%
2023-02-09SaleSakys JohnCFO
1,000
0.0194%
$184.27
$184,270
-28.37%
Total: 256
*Gray background shows transactions not older than one year

Insider Historical Profitability

17.59%
Owens Gary MPresident and CEO
45824
0.8294%
$4.72M012
Sakys JohnCFO
12865
0.2329%
$1.33M030
Ladiwala Shiraz Shabanalidirector
8523
0.1543%
$878,380.3810
Tripeny R Tonydirector
5398
0.0977%
$556,317.8820
<0.0001%
Capone Mark Christopherdirector
3429
0.0621%
$353,392.7410
Archbold Brian DavidSVP Operations
558
0.0101%
$57,507.48012
SEG Ventures, LLCdirector
200000
3.62%
$20.61M40
SCHMIEDER LUKE Rdirector
172488
3.1221%
$17.78M02
DUKE PAUL Ddirector
70043
1.2678%
$7.22M011
Schmieder John Bradleydirector
62760
1.136%
$6.47M018
CAMPBELL H STUARTdirector
41527
0.7516%
$4.28M122
<0.0001%
Dwyer Robert Vdirector
35696
0.6461%
$3.68M226
GUILLEMIN EVAN
28776
0.5209%
$2.97M419
BROOKS MICHAEL Tdirector
27750
0.5023%
$2.86M04
Sullivan John Jamesdirector
23857
0.4318%
$2.46M535
PETERSON STEVEN W
21362
0.3867%
$2.2M09
Adriance Glenn ECSMO
10000
0.181%
$1.03M19
+36.21%
DINOIA GREGORYSVP Commercial
3634
0.0658%
$374,520.0408
KELLY DAVID Mdirector
2600
0.0471%
$267,956.00314
+33.16%
Hall Shannondirector
957
0.0173%
$98,628.4201
*Gray background shows insiders who have made transactions during last year

MLAB Institutional Investors: Active Positions

Increased Positions93+63.7%1M+23.38%
Decreased Positions61-41.78%1M-26.88%
New Positions39New571,714New
Sold Out Positions14Sold Out827,451Sold Out
Total Postitions178+21.92%5M-3.5%

MLAB Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Conestoga Capital Advisors, Llc$33,873.007.11%426,457-139,693-24.67%2025-09-30
Blackrock, Inc.$30,882.006.48%388,795-402,332-50.86%2025-09-30
Vanguard Group Inc$25,554.005.36%321,717-67,692-17.38%2025-09-30
Morgan Stanley$20,253.004.25%254,974+36,178+16.54%2025-09-30
Ranger Investment Management, L.P.$16,656.003.5%209,700-4,590-2.14%2025-09-30
Geneva Capital Management Llc$15,202.003.19%191,386-7,706-3.87%2025-09-30
Simcoe Capital Management, Llc$15,165.003.18%190,929+190,929New2025-09-30
Royce & Associates Lp$11,800.002.48%148,558-99,048-40%2025-09-30
Glenmede Trust Co Na$11,640.002.44%146,544-5,303-3.49%2025-03-31
Janus Henderson Group Plc$11,569.002.43%145,654+32,369+28.57%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.